HF
SCNI

HRT Financial’s Scinai Immunotherapeutics SCNI Stock Holding History

HRT Financial’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Buy
+1,209
New +$5.95K ﹤0.01% 4036
2021
Q4 		– Sell
-36
Closed -$78K – 3970
2021
Q3 		$78K Buy
36
+4
+13% +$10.3K ﹤0.01% 2965
2021
Q2 		$92K Hold
32
– – ﹤0.01% 2606
2021
Q1 		$121K Buy
+32
New +$140K ﹤0.01% 2429

Other funds holding SCNI

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial's SCNI Position: Q2 2026 in Review

HRT Financial opened a new position in Scinai Immunotherapeutics (SCNI) in Q2 2026: 1,209 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #4036 among its holdings. This is a return to the name: HRT Financial previously reported a position in SCNI as recently as Q3 2021.

HRT Financial first reported a position in SCNI in Q1 2021 and has held it in 4 quarters since. The position peaked at $121K in Q1 2021. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

  • HRT Financial held 1,209 shares of Scinai Immunotherapeutics worth $3K as of Q2 2026.
  • Scinai Immunotherapeutics was a new HRT Financial position in Q2 2026.
  • Scinai Immunotherapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #4036 holding.
  • HRT Financial first reported a position in Scinai Immunotherapeutics in Q1 2021 and has held it in 4 quarters since.
  • HRT Financial's Scinai Immunotherapeutics position peaked at $121K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.